{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T00:57:45Z","timestamp":1760144265996,"version":"build-2065373602"},"reference-count":87,"publisher":"Elsevier BV","issue":"8","license":[{"start":{"date-parts":[[2022,10,1]],"date-time":"2022-10-01T00:00:00Z","timestamp":1664582400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,10,1]],"date-time":"2022-10-01T00:00:00Z","timestamp":1664582400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,10,3]],"date-time":"2023-10-03T00:00:00Z","timestamp":1696291200000},"content-version":"am","delay-in-days":367,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Revue des Maladies Respiratoires"],"published-print":{"date-parts":[[2022,10]]},"DOI":"10.1016\/j.rmr.2022.08.005","type":"journal-article","created":{"date-parts":[[2022,8,30]],"date-time":"2022-08-30T07:48:42Z","timestamp":1661845722000},"page":"685-697","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["BPCO et \u00e9osinophiles"],"prefix":"10.1016","volume":"39","author":[{"given":"M.","family":"Gue\u00e7amburu","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M.","family":"Zysman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.rmr.2022.08.005_bib0440","unstructured":"The top 10\u00a0causes of death [Internet]. [cit\u00e9 12\u00a0juin 2022]. Disponible sur: https:\/\/www.who.int\/news-room\/fact-sheets\/detail\/the-top-10-causes-of-death."},{"key":"10.1016\/j.rmr.2022.08.005_bib0445","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1007\/s00408-021-00492-0","article-title":"Eosinophilic chronic obstructive pulmonary disease","volume":"199","author":"Weissler","year":"2021","journal-title":"Lung"},{"key":"10.1016\/j.rmr.2022.08.005_bib0450","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1186\/s12931-018-0807-y","article-title":"The association between airway eosinophilic inflammation and IL-33\u00a0in stable non-atopic COPD","volume":"19","author":"Tworek","year":"2018","journal-title":"Respir Res"},{"key":"10.1016\/j.rmr.2022.08.005_bib0455","doi-asserted-by":"crossref","first-page":"1114","DOI":"10.1164\/rccm.200506-859OC","article-title":"Infections and airway inflammation in chronic obstructive pulmonary disease severe exacerbations","volume":"173","author":"Papi","year":"2006","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.rmr.2022.08.005_bib0460","doi-asserted-by":"crossref","first-page":"1305","DOI":"10.3904\/kjim.2021.180","article-title":"Eosinophilic endotype of chronic obstructive pulmonary disease: similarities and differences from asthma","volume":"36","author":"Li","year":"2021","journal-title":"Korean J Intern Med"},{"key":"10.1016\/j.rmr.2022.08.005_bib0465","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1146\/annurev.immunol.24.021605.090720","article-title":"The eosinophil","volume":"24","author":"Rothenberg","year":"2006","journal-title":"Annu Rev Immunol"},{"key":"10.1016\/j.rmr.2022.08.005_bib0470","doi-asserted-by":"crossref","DOI":"10.1183\/13993003.00110-2019","article-title":"Eosinophils, basophils and type 2\u00a0immune microenvironments in COPD-affected lung tissue","volume":"55","author":"Jogdand","year":"2020","journal-title":"Eur Respir J"},{"key":"10.1016\/j.rmr.2022.08.005_bib0475","doi-asserted-by":"crossref","first-page":"758","DOI":"10.1164\/rccm.201408-1458OC","article-title":"Asthma-COPD overlap. Clinical relevance of genomic signatures of type 2\u00a0inflammation in chronic obstructive pulmonary disease","volume":"191","author":"Christenson","year":"2015","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.rmr.2022.08.005_bib0480","unstructured":"GINA_GOLD_ACOS_2014-wms.pdf [Internet]. [cit\u00e9 30\u00a0juill 2022]. Disponible sur: https:\/\/ginasthma.org\/wp-content\/uploads\/2019\/11\/GINA_GOLD_ACOS_2014-wms.pdf."},{"key":"10.1016\/j.rmr.2022.08.005_bib0485","doi-asserted-by":"crossref","first-page":"708","DOI":"10.3390\/jpm12050708","article-title":"Asthma-COPD overlap syndrome: recent insights and unanswered questions","volume":"12","author":"Fouka","year":"2022","journal-title":"J Pers Med"},{"key":"10.1016\/j.rmr.2022.08.005_bib0490","doi-asserted-by":"crossref","first-page":"2079","DOI":"10.1111\/all.14741","article-title":"Molecular markers of type 2\u00a0airway inflammation are similar between eosinophilic severe asthma and eosinophilic chronic obstructive pulmonary disease","volume":"76","author":"Fricker","year":"2021","journal-title":"Allergy"},{"key":"10.1016\/j.rmr.2022.08.005_bib0495","doi-asserted-by":"crossref","first-page":"1646","DOI":"10.1164\/ajrccm.150.6.7952628","article-title":"Airway eosinophilia in chronic bronchitis during exacerbations","volume":"150","author":"Saetta","year":"1994","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.rmr.2022.08.005_bib0500","doi-asserted-by":"crossref","unstructured":"Saetta M, Di Stefano A, Maestrelli P, Turato G, Mapp Ce, Pieno M, et al. Airway eosinophilia and expression of interleukin-5\u00a0protein in asthma and in exacerbations of chronic bronchitis. Clinical & Experimental Allergy;26:766-74.","DOI":"10.1111\/j.1365-2222.1996.tb00606.x"},{"key":"10.1016\/j.rmr.2022.08.005_bib0505","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1111\/all.14016","article-title":"Blood eosinophil count and airway epithelial transcriptome relationships in COPD versus asthma","volume":"75","author":"George","year":"2020","journal-title":"Allergy"},{"key":"10.1016\/j.rmr.2022.08.005_bib0510","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1093\/ajcp\/88.2.182","article-title":"The determination of reference values for hematologic parameters using results obtained from patient populations","volume":"88","author":"Swaanenburg","year":"1987","journal-title":"Am J Clin Pathol"},{"key":"10.1016\/j.rmr.2022.08.005_bib0515","doi-asserted-by":"crossref","first-page":"96","DOI":"10.4314\/mmj.v27i3.5","article-title":"A pilot study to determine the normal haematological indices for young Malawian adults in Blantyre, Malawi","volume":"27","author":"Chisale","year":"2015","journal-title":"Malawi Med J"},{"key":"10.1016\/j.rmr.2022.08.005_bib0520","doi-asserted-by":"crossref","first-page":"965","DOI":"10.1164\/rccm.201509-1869OC","article-title":"Blood eosinophils and exacerbations in chronic obstructive pulmonary disease. the copenhagen general population study","volume":"193","author":"Vedel-Krogh","year":"2016","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.rmr.2022.08.005_bib0525","unstructured":"SANTE MF. Orientations diagnostiques face \u00e0 une hyper\u00e9osinophilie [Internet]. MaRIH FILIERE SANTE. [cit\u00e9 31\u00a0juill 2022]. Disponible sur: http:\/\/www.cereo.fr\/website\/orientations_diag_&400&8.html."},{"key":"10.1016\/j.rmr.2022.08.005_bib0530","doi-asserted-by":"crossref","first-page":"1495","DOI":"10.2147\/COPD.S100338","article-title":"Peripheral blood eosinophils: a surrogate marker for airway eosinophilia in stable COPD","volume":"11","author":"Negewo","year":"2016","journal-title":"Int J Chron Obstruct Pulmon Dis"},{"key":"10.1016\/j.rmr.2022.08.005_bib0535","doi-asserted-by":"crossref","first-page":"382","DOI":"10.1080\/15412555.2017.1313827","article-title":"Stability of blood eosinophil count in patients with COPD in the UK clinical practice research datalink","volume":"14","author":"Landis","year":"2017","journal-title":"COPD"},{"key":"10.1016\/j.rmr.2022.08.005_bib0540","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1186\/s12931-020-1279-4","article-title":"The stability of blood Eosinophils in chronic obstructive pulmonary disease","volume":"21","author":"Long","year":"2020","journal-title":"Respir Res"},{"key":"10.1016\/j.rmr.2022.08.005_bib0545","doi-asserted-by":"crossref","first-page":"1800427","DOI":"10.1183\/13993003.00427-2018","article-title":"The reproducibility of COPD blood eosinophil counts","volume":"52","author":"Southworth","year":"2018","journal-title":"Eur Respir J"},{"key":"10.1016\/j.rmr.2022.08.005_bib0550","doi-asserted-by":"crossref","first-page":"1901874","DOI":"10.1183\/13993003.01874-2019","article-title":"Blood eosinophil count in the general population: typical values and potential confounders","volume":"55","author":"Hartl","year":"2020","journal-title":"Eur Respir J"},{"key":"10.1016\/j.rmr.2022.08.005_bib0555","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1093\/ajcp\/75.5.693","article-title":"Within-day physiologic variation of leukocyte types in healthy subjects as assayed by two automated leukocyte differential analyzers","volume":"75","author":"Winkel","year":"1981","journal-title":"Am J Clin Pathol"},{"issue":"5","key":"10.1016\/j.rmr.2022.08.005_bib0560","doi-asserted-by":"crossref","first-page":"2000622","DOI":"10.1183\/13993003.00622-2020","article-title":"Stability of eosinophilic inflammation in COPD bronchial biopsies.","volume":"56","author":"Higham","year":"2020","journal-title":"Eur Respir J"},{"key":"10.1016\/j.rmr.2022.08.005_bib0565","doi-asserted-by":"crossref","first-page":"1216","DOI":"10.1164\/rccm.201708-1684LE","article-title":"Blood eosinophilia neither reflects tissue eosinophils nor worsens clinical outcomes in chronic obstructive pulmonary disease","volume":"197","author":"Turato","year":"2018","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.rmr.2022.08.005_bib0570","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1111\/resp.13607","article-title":"Airway inflammatory profile is correlated with symptoms in stable COPD: a longitudinal proof-of-concept cohort study","volume":"25","author":"Contoli","year":"2020","journal-title":"Respirology"},{"key":"10.1016\/j.rmr.2022.08.005_bib0575","doi-asserted-by":"crossref","first-page":"956","DOI":"10.1016\/S2213-2600(17)30432-0","article-title":"Sputum or blood eosinophil association with clinical measures of COPD severity in the SPIROMICS cohort","volume":"5","author":"Hastie","year":"2017","journal-title":"Lancet Respir Med"},{"key":"10.1016\/j.rmr.2022.08.005_bib0580","doi-asserted-by":"crossref","first-page":"1819","DOI":"10.2147\/COPD.S129787","article-title":"Relationship between blood eosinophils, clinical characteristics, and mortality in patients with COPD","volume":"12","author":"Zysman","year":"2017","journal-title":"Int J Chron Obstruct Pulmon Dis"},{"key":"10.1016\/j.rmr.2022.08.005_bib0585","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1164\/rccm.202201-0209PP","article-title":"Blood eosinophils and chronic obstructive pulmonary disease: a global initiative for chronic obstructive lung disease science committee 2022\u00a0review","volume":"206","author":"Singh","year":"2022","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.rmr.2022.08.005_bib0590","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1164\/rccm.200901-0047OC","article-title":"The natural history of chronic airflow obstruction revisited: an analysis of the Framingham offspring cohort","volume":"180","author":"Kohansal","year":"2009","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.rmr.2022.08.005_bib0595","doi-asserted-by":"crossref","first-page":"879","DOI":"10.1016\/j.chest.2021.04.009","article-title":"Impaired respiratory health and life course transitions from health to chronic lung disease","volume":"160","author":"Liu","year":"2021","journal-title":"Chest"},{"key":"10.1016\/j.rmr.2022.08.005_bib0600","first-page":"6535","article-title":"Childhood predictors of lung function trajectories and future COPD risk: a prospective cohort study from the first to the sixth decade of life","author":"Bui","year":"2018","journal-title":"Lancet Respir Med"},{"key":"10.1016\/j.rmr.2022.08.005_bib0605","doi-asserted-by":"crossref","first-page":"1702536","DOI":"10.1183\/13993003.02536-2017","article-title":"Associations between blood eosinophils and decline in lung function among adults with and without asthma","volume":"51","author":"Hancox","year":"2018","journal-title":"Eur Respir J"},{"key":"10.1016\/j.rmr.2022.08.005_bib0610","doi-asserted-by":"crossref","first-page":"2000838","DOI":"10.1183\/13993003.00838-2020","article-title":"High eosinophil counts predict decline in FEV1: results from the CanCOLD study","volume":"57","author":"Tan","year":"2021","journal-title":"Eur Respir J"},{"key":"10.1016\/j.rmr.2022.08.005_bib0615","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1186\/1465-9921-10-113","article-title":"Eosinophil and T cell markers predict functional decline in COPD patients","volume":"10","author":"D\u2019Armiento","year":"2009","journal-title":"Respir Res"},{"key":"10.1016\/j.rmr.2022.08.005_bib0620","doi-asserted-by":"crossref","first-page":"1155","DOI":"10.2147\/COPD.S80992","article-title":"Bronchial hyperresponsiveness, airway inflammation, and reversibility in patients with chronic obstructive pulmonary disease","volume":"10","author":"Zanini","year":"2015","journal-title":"Int J Chron Obstruct Pulmon Dis"},{"key":"10.1016\/j.rmr.2022.08.005_bib0625","doi-asserted-by":"crossref","first-page":"747","DOI":"10.1016\/S2213-2600(18)30327-8","volume":"6","author":"Ferguson","year":"2018","journal-title":"Lancet Respir Med"},{"key":"10.1016\/j.rmr.2022.08.005_bib0630","doi-asserted-by":"crossref","first-page":"2222","DOI":"10.1056\/NEJMoa1516385","article-title":"Indacaterol-Glycopyrronium versus Salmeterol-Fluticasone for COPD","volume":"374","author":"Wedzicha","year":"2016","journal-title":"N Engl J Med"},{"key":"10.1016\/j.rmr.2022.08.005_bib0635","doi-asserted-by":"crossref","first-page":"963","DOI":"10.1016\/S0140-6736(16)31354-X","article-title":"Single inhaler triple therapy versus inhaled corticosteroid plus long-acting \u03b22-agonist therapy for chronic obstructive pulmonary disease (TRILOGY): a double-blind, parallel group, randomised controlled trial","volume":"388","author":"Singh","year":"2016","journal-title":"The Lancet"},{"key":"10.1016\/j.rmr.2022.08.005_bib0640","doi-asserted-by":"crossref","first-page":"1671","DOI":"10.1056\/NEJMoa1713901","article-title":"Once-daily single-inhaler triple versus dual therapy in patients with COPD","volume":"378","author":"Lipson","year":"2018","journal-title":"N Engl J Med"},{"key":"10.1016\/j.rmr.2022.08.005_bib0645","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1056\/NEJMoa1916046","article-title":"Triple inhaled therapy at two glucocorticoid doses in moderate-to-very-severe COPD","volume":"383","author":"Rabe","year":"2020","journal-title":"N Engl J Med"},{"key":"10.1016\/j.rmr.2022.08.005_bib0650","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1016\/S2213-2600(18)30006-7","article-title":"Predictors of exacerbation risk and response to budesonide in patients with chronic obstructive pulmonary disease: a post-hoc analysis of three randomised trials","volume":"6","author":"Bafadhel","year":"2018","journal-title":"Lancet Respir Med"},{"key":"10.1016\/j.rmr.2022.08.005_bib0655","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1016\/S2213-2600(15)00106-X","article-title":"Blood eosinophil counts, exacerbations, and response to the addition of inhaled fluticasone furoate to vilanterol in patients with chronic obstructive pulmonary disease: a secondary analysis of data from two parallel randomised controlled trials","volume":"3","author":"Pascoe","year":"2015","journal-title":"Lancet Respir Medicine"},{"key":"10.1016\/j.rmr.2022.08.005_bib0660","doi-asserted-by":"crossref","first-page":"1189","DOI":"10.1164\/rccm.201701-0193OC","article-title":"Blood eosinophils and response to maintenance COPD treatment: data from the FLAME Trial. American Journal of Respiratory and Critical Care Medicine. 9\u00a0mars 2017;195","volume":"195","author":"Roche","year":"2017","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.rmr.2022.08.005_bib0665","doi-asserted-by":"crossref","DOI":"10.1002\/14651858.CD002991.pub3","article-title":"Inhaled corticosteroids for stable chronic obstructive pulmonary disease","author":"Yang","year":"2012","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.rmr.2022.08.005_bib0670","doi-asserted-by":"crossref","first-page":"1158","DOI":"10.1016\/j.chest.2019.03.005","article-title":"Comparative effectiveness and safety of LABA-LAMA vs LABA-ICS treatment of COPD in real-world clinical practice","volume":"155","author":"Suissa","year":"2019","journal-title":"Chest"},{"key":"10.1016\/j.rmr.2022.08.005_bib0675","doi-asserted-by":"crossref","first-page":"390","DOI":"10.1016\/S2213-2600(16)00100-4","article-title":"Blood eosinophil count and exacerbations in severe chronic obstructive pulmonary disease after withdrawal of inhaled corticosteroids: a post-hoc analysis of the WISDOM trial","volume":"4","author":"Watz","year":"2016","journal-title":"Lancet Respir Med"},{"key":"10.1016\/j.rmr.2022.08.005_bib0680","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1164\/rccm.201803-0405OC","article-title":"Long-term triple therapy de-escalation to indacaterol\/glycopyrronium in patients with chronic obstructive pulmonary disease (SUNSET): a randomized, double-blind, triple-dummy clinical trial","volume":"198","author":"Chapman","year":"2018","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.rmr.2022.08.005_bib0685","unstructured":"2022\u00a0GOLD Reports [Internet]. Global Initiative for Chronic Obstructive Lung Disease - GOLD. [cit\u00e9 20\u00a0avr 2022]. Disponible sur: https:\/\/goldcopd.org\/2022-gold-reports-2\/."},{"key":"10.1016\/j.rmr.2022.08.005_bib0690","first-page":"A2780","article-title":"Adverse Outcomes Post-Initiation of Systemic Corticosteroids in Patients with Chronic Obstructive Pulmonary Disease: A Long-Term Observational UK-Based Study","author":"Price","year":"2022","journal-title":"Am J Respir Critr Care Med"},{"key":"10.1016\/j.rmr.2022.08.005_bib0695","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1016\/j.ypdi.2012.01.014","article-title":"Acute exacerbations of chronic obstructive pulmonary disease: identification of biologic clusters and their biomarkers","volume":"2012","author":"Maurer","year":"2012","journal-title":"Yearbook of Pulmonary Disease"},{"key":"10.1016\/j.rmr.2022.08.005_bib0700","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1164\/rccm.201108-1553OC","article-title":"Blood eosinophils to direct corticosteroid treatment of exacerbations of chronic obstructive pulmonary disease: a randomized placebo-controlled trial","volume":"186","author":"Bafadhel","year":"2012","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.rmr.2022.08.005_bib0705","doi-asserted-by":"crossref","DOI":"10.1183\/13993003.00791-2016","article-title":"Management of COPD exacerbations: a European Respiratory Society\/American Thoracic Society guideline","volume":"49","author":"Wedzicha","year":"2017","journal-title":"Eur Respir J"},{"key":"10.1016\/j.rmr.2022.08.005_bib0710","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1183\/09031936.00062614","article-title":"Blood eosinophil guided prednisolone therapy for exacerbations of COPD: a further analysis","volume":"44","author":"Bafadhel","year":"2014","journal-title":"Eur Respir J"},{"key":"10.1016\/j.rmr.2022.08.005_bib0715","doi-asserted-by":"crossref","unstructured":"Mi M, Cr O, L B, K H, P L, A W, et al. Low and High Blood Eosinophil Counts as Biomarkers in Hospitalized Acute Exacerbations of COPD. Chest [Internet]. juill 2019 [cit\u00e9 24\u00a0juin 2022];156(1). Disponible sur: https:\/\/pubmed.ncbi.nlm.nih.gov\/30978330\/.","DOI":"10.1016\/j.chest.2019.02.406"},{"key":"10.1016\/j.rmr.2022.08.005_bib0720","doi-asserted-by":"crossref","first-page":"970","DOI":"10.1136\/thoraxjnl-2012-202103","article-title":"The DECAF Score: predicting hospital mortality in exacerbations of chronic obstructive pulmonary disease","volume":"67","author":"Steer","year":"2012","journal-title":"Thorax"},{"key":"10.1016\/j.rmr.2022.08.005_bib0725","doi-asserted-by":"crossref","first-page":"726","DOI":"10.1378\/chest.119.3.726","article-title":"Systemic glucocorticoids in severe exacerbations of COPD","volume":"119","author":"Sayiner","year":"2001","journal-title":"Chest"},{"key":"10.1016\/j.rmr.2022.08.005_bib0730","doi-asserted-by":"crossref","first-page":"2223","DOI":"10.1001\/jama.2013.5023","article-title":"Short-term vs conventional glucocorticoid therapy in acute exacerbations of chronic obstructive pulmonary disease: the REDUCE randomized clinical trial","volume":"309","author":"Leuppi","year":"2013","journal-title":"JAMA"},{"key":"10.1016\/j.rmr.2022.08.005_bib0735","article-title":"Outcomes reported on the management of COPD exacerbations: a systematic survey of randomised controlled trials","volume":"5","author":"Mathioudakis","year":"2019","journal-title":"ERJ Open Res"},{"issue":"8","key":"10.1016\/j.rmr.2022.08.005_bib0740","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1016\/S2213-2600(19)30176-6","article-title":"Eosinophil-guided corticosteroid therapy in patients admitted to hospital with COPD exacerbation (CORTICO-COP): a multicentre, randomised, controlled, open-label, non-inferiority trial","volume":"7","author":"Sivapalan","year":"2019","journal-title":"Lancet Respir Med"},{"key":"10.1016\/j.rmr.2022.08.005_bib0745","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2019-035811","article-title":"Prioritising outcomes for evaluating eosinophil-guided corticosteroid therapy among patients with acute COPD exacerbations requiring hospitalisation: a Delphi consensus study","volume":"10","author":"Suehs","year":"2020","journal-title":"BMJ Open"},{"key":"10.1016\/j.rmr.2022.08.005_bib0750","unstructured":"University Hospital, Montpellier. Eosinophil-driven Corticotherapy for Patients Hospitalized for COPD Exacerbation: a Double-blind, Randomized, Controlled Trial [Internet]. clinicaltrials.gov; 2022\u00a0juin [cit\u00e9 23\u00a0juin 2022]. Report No.: NCT04234360. Disponible sur: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04234360."},{"key":"10.1016\/j.rmr.2022.08.005_bib0755","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1080\/15412555.2018.1437897","article-title":"Biologic drugs: a new target therapy in COPD?","volume":"15","author":"Yousuf","year":"2018","journal-title":"COPD: Journal of Chronic Obstructive Pulmonary Disease"},{"key":"10.1016\/j.rmr.2022.08.005_bib0760","doi-asserted-by":"crossref","first-page":"926","DOI":"10.1378\/chest.126.3.926","article-title":"Efficacy and safety of a monoclonal antibody recognizing interleukin-8\u00a0in COPD","volume":"126","author":"Mahler","year":"2004","journal-title":"Chest"},{"key":"10.1016\/j.rmr.2022.08.005_bib0765","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1186\/s12931-017-0633-7","article-title":"A randomised, placebo-controlled trial of anti\u2013interleukin-1\u00a0receptor 1\u00a0monoclonal antibody MEDI8968\u00a0in chronic obstructive pulmonary disease","volume":"18","author":"Calverley","year":"2017","journal-title":"Respir Res"},{"key":"10.1016\/j.rmr.2022.08.005_bib0770","doi-asserted-by":"crossref","first-page":"926","DOI":"10.1164\/rccm.200607-995OC","article-title":"The safety and efficacy of infliximab in moderate to severe chronic obstructive pulmonary disease","volume":"175","author":"Rennard","year":"2007","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.rmr.2022.08.005_bib0775","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1136\/thoraxjnl-2012-202432","article-title":"TNF\u03b1 antagonists for acute exacerbations of COPD: a randomised double-blind controlled trial","volume":"68","author":"Aaron","year":"2013","journal-title":"Thorax"},{"key":"10.1016\/j.rmr.2022.08.005_bib0780","doi-asserted-by":"crossref","first-page":"891","DOI":"10.1016\/S2213-2600(14)70187-0","article-title":"Benralizumab for chronic obstructive pulmonary disease and sputum eosinophilia: a randomised, double-blind, placebo-controlled, phase 2a study","volume":"2","author":"Brightling","year":"2014","journal-title":"Lancet Respir Med"},{"key":"10.1016\/j.rmr.2022.08.005_bib0785","doi-asserted-by":"crossref","first-page":"1023","DOI":"10.1056\/NEJMoa1905248","article-title":"Benralizumab for the Prevention of COPD Exacerbations","volume":"381","author":"Criner","year":"2019","journal-title":"N Engl J Med"},{"key":"10.1016\/j.rmr.2022.08.005_bib0790","unstructured":"AstraZeneca. A Multicenter, Randomized, Double-blind, Chronic-dosing, Parallel-group, Placebo-controlled Phase 3\u00a0Study to Evaluate the Efficacy and Safety of Benralizumab 100mg in Patients With Moderate to Very Severe Chronic Obstructive Pulmonary Disease (COPD) With a History of Frequent COPD Exacerbations and Elevated Peripheral Blood Eosinophils (RESOLUTE) [Internet]. clinicaltrials.gov; 2022\u00a0avr [cit\u00e9 24\u00a0mai 2022]. Report No.: NCT04053634. Disponible sur: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04053634."},{"key":"10.1016\/j.rmr.2022.08.005_bib0795","doi-asserted-by":"crossref","unstructured":"Dasgupta A., Kjarsgaard M., Capaldi D., et al. A pilot randomised clinical trial of mepolizumab in COPD with eosinophilic bronchitis. Eur Respir J. 2017 Mar 15;49(3):1602486.","DOI":"10.1183\/13993003.02486-2016"},{"key":"10.1016\/j.rmr.2022.08.005_bib0800","doi-asserted-by":"crossref","first-page":"1613","DOI":"10.1056\/NEJMoa1708208","article-title":"Mepolizumab for eosinophilic chronic obstructive pulmonary disease","volume":"377","author":"Pavord","year":"2017","journal-title":"N Engl J Med"},{"key":"10.1016\/j.rmr.2022.08.005_bib0805","doi-asserted-by":"crossref","first-page":"1755","DOI":"10.2147\/COPD.S294333","article-title":"Mepolizumab for Eosinophil-Associated COPD: Analysis of METREX and METREO","volume":"16","author":"Pavord","year":"2021","journal-title":"Int J Chron Obstruct Pulmon Dis"},{"key":"10.1016\/j.rmr.2022.08.005_bib0810","unstructured":"GlaxoSmithKline. A Multi-center, Randomized, Double-blind, Parallel-group, Placebo-controlled Study of Mepolizumab 100mg SC as add-on Treatment in Participants With COPD Experiencing Frequent Exacerbations and Characterized by Eosinophil Levels (Study 208657) [Internet]. clinicaltrials.gov; 2022\u00a0mars [cit\u00e9 24\u00a0mai 2022]. Report No.: NCT04133909. Disponible sur: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04133909."},{"key":"10.1016\/j.rmr.2022.08.005_bib0815","unstructured":"Sanofi. A Randomized, Double-blind, Placebo-controlled, Parallel-group, 52-week Pivotal Study to Assess the Efficacy, Safety, and Tolerability of Dupilumab in Patients With Moderate-to-severe Chronic Obstructive Pulmonary Disease (COPD) With Type 2\u00a0Inflammation [Internet]. clinicaltrials.gov; 2022\u00a0mai [cit\u00e9 24\u00a0mai 2022]. Report No.: NCT04456673. Disponible sur: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04456673."},{"key":"10.1016\/j.rmr.2022.08.005_bib0820","doi-asserted-by":"crossref","first-page":"777","DOI":"10.1080\/14728222.2020.1783242","article-title":"Thymic stromal lymphopoietin: its role and potential as a therapeutic target in asthma","volume":"24","author":"Gauvreau","year":"2020","journal-title":"Expert Opinion on Therapeutic Targets"},{"key":"10.1016\/j.rmr.2022.08.005_bib0825","doi-asserted-by":"crossref","first-page":"936","DOI":"10.1056\/NEJMoa1704064","article-title":"Tezepelumab in adults with uncontrolled asthma","volume":"377","author":"Corren","year":"2017","journal-title":"N Engl J Med"},{"key":"10.1016\/j.rmr.2022.08.005_bib0830","unstructured":"AstraZeneca. A Randomized, Double-blind, Placebo-controlled, Parallel Group, Multicenter Phase 2a Study to Explore the Efficacy and Safety of Tezepelumab in Patients With Moderate to Very Severe Chronic Obstructive Pulmonary Disease (COPD) (COURSE) [Internet]. clinicaltrials.gov; 2022\u00a0mai [cit\u00e9 25\u00a0mai 2022]. Report No.: NCT04039113. Disponible sur: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04039113."},{"key":"10.1016\/j.rmr.2022.08.005_bib0835","doi-asserted-by":"crossref","first-page":"1373","DOI":"10.1164\/rccm.201406-1039OC","article-title":"IL-33-dependent type 2\u00a0inflammation during rhinovirus-induced asthma exacerbations in vivo","volume":"190","author":"Jackson","year":"2014","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.rmr.2022.08.005_bib0840","first-page":"A2397","article-title":"Proof of Mechanism for Anti-Interleukin-33 Antibody Tozorakimab in a Phase 1 Study in Healthy Adults and Patients with Chronic Obstructive Pulmonary Disease","author":"Scott","year":"2022","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.rmr.2022.08.005_bib0845","series-title":"American Thoracic Society","first-page":"A2398","article-title":"Pharmacokinetics and Immunogenicity of the Anti-Interleukin-33 Antibody, Tozorakimab: Results of a Phase 1 Study in Healthy Adults and Patients with Chronic Obstructive Pulmonary Disease.","author":"Reid","year":"2022"},{"key":"10.1016\/j.rmr.2022.08.005_bib0850","doi-asserted-by":"crossref","first-page":"1288","DOI":"10.1016\/S2213-2600(21)00167-3","article-title":"Safety and efficacy of itepekimab in patients with moderate-to-severe COPD: a genetic association study and randomised, double-blind, phase 2a trial","volume":"9","author":"Rabe","year":"2021","journal-title":"Lancet Respir Med"},{"key":"10.1016\/j.rmr.2022.08.005_bib0855","unstructured":"Sanofi. Randomized, Double-blind, Placebo-controlled, Parallel Group Phase 3\u00a0Study to Evaluate the Efficacy, Safety, and Tolerability of SAR440340\/REGN3500\/Itepekimab (Anti-IL-33\u00a0mAb) in Patients With Moderate-to-severe Chronic Obstructive Pulmonary Disease (COPD) [Internet]. clinicaltrials.gov; 2022\u00a0mai [cit\u00e9 25\u00a0mai 2022]. Report No.: NCT04701983. Disponible sur: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04701983."},{"key":"10.1016\/j.rmr.2022.08.005_bib0860","doi-asserted-by":"crossref","first-page":"1919","DOI":"10.1016\/S0140-6736(17)30188-5","article-title":"Single inhaler extrafine triple therapy versus long-acting muscarinic antagonist therapy for chronic obstructive pulmonary disease (TRINITY): a double-blind, parallel group, randomised controlled trial","volume":"389","author":"Vestbo","year":"2017","journal-title":"Lancet"},{"key":"10.1016\/j.rmr.2022.08.005_bib0865","doi-asserted-by":"crossref","first-page":"1076","DOI":"10.1016\/S0140-6736(18)30206-X","article-title":"Extrafine inhaled triple therapy versus dual bronchodilator therapy in chronic obstructive pulmonary disease (TRIBUTE): a double-blind, parallel group, randomised controlled trial","volume":"391","author":"Papi","year":"2018","journal-title":"Lancet"},{"key":"10.1016\/j.rmr.2022.08.005_bib0435","unstructured":"Hoffmann-La Roche. A Phase II, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy and Safety of Lebrikizumab in Patients With Chronic Obstructive Pulmonary Disease and a History of Exacerbations [Internet]. clinicaltrials.gov; 2017\u00a0sept [cit\u00e9 27\u00a0juill 2022]. Report No.: NCT02546700. Disponible sur: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT02546700."}],"container-title":["Revue des Maladies Respiratoires"],"original-title":[],"language":"fr","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0761842522002807?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0761842522002807?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T14:24:04Z","timestamp":1760106244000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0761842522002807"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,10]]},"references-count":87,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2022,10]]}},"alternative-id":["S0761842522002807"],"URL":"https:\/\/doi.org\/10.1016\/j.rmr.2022.08.005","relation":{},"ISSN":["0761-8425"],"issn-type":[{"type":"print","value":"0761-8425"}],"subject":[],"published":{"date-parts":[[2022,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"BPCO et \u00e9osinophiles","name":"articletitle","label":"Article Title"},{"value":"Revue des Maladies Respiratoires","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.rmr.2022.08.005","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 SPLF. Published by Elsevier Masson SAS. All rights reserved.","name":"copyright","label":"Copyright"}]}}